医学
观察研究
苯二氮卓
叙述性评论
人口
折旧
精神科
催眠药
中止
重症监护医学
药方
随机对照试验
梅德林
德尔菲法
药品
多药
系统回顾
期望理论
镇静
荟萃分析
作者
Göran Hajak,Ingo Fietze,Christoph Schöbel,Michael Saletu,Birgit Högl,Yaroslav Winter
出处
期刊:PubMed
[National Institutes of Health]
日期:2026-09-18
卷期号:123 (19)
标识
DOI:10.3238/arztebl.m2026.0141
摘要
BACKGROUND: 10-30% of the world's population suffers from insomnia. One-quarter of those who take hypnotic medication become dependent on it. Given the wide variety of available drugs, switching them is complex. The existing recommendations do not cover all drug classes. There is a need for practical, evidence-based recommendations that take account of specific aspects of care both in Europe as a whole and regionally. METHODS: This narrative review is based on publications from May 1953 to February 2026 that were retrieved by a search in six English- and German-language databases, including guidelines, meta-analyses, systematic reviews, randomized controlled trials, and observational studies. Following the literature review, new recommendations were developed in a consensus process (consensus conference followed by the Delphi method) to supplement the current insomnia guideline. RESULTS: Treatment can be discontinued abruptly after short-term use (1-2 weeks) or if the drug in question does not produce withdrawal symptoms, e.g., daridorexant (an orexin receptor antagonist), melatonin, antihistamines, and phytotherapeutic drugs. Benzodiazepine receptor agonists, antidepressants, antipsychotics, and gabapentinoids should be tapered off gradually after medium- or long-term use (> 2 weeks), with a weekly dose reduction of 10-25%. Various gradual tapering methods can be used, depending on the drug, dose, duration of use, treatment regimen, and intended subsequent treatment. A longer taper is advisable after use at high doses (≥ 2/3 of the maximum dose) or over the long term (≥ 1 year). Withdrawal symptoms from benzodiazepine receptor agonists can be alleviated with the overlapping administration of daridorexant or eszopiclone. Behavioral therapy is recommended as an accompanying nonpharmacological treatment (relative risk [RR]: 1.68; 95% confidence interval: [1.19; 2.39]). CONCLUSION: A drug-specific approach with evidence-based and practice-oriented protocols should be used when hypnotic medications are switched or discontinued.
科研通智能强力驱动
Strongly Powered by AbleSci AI